All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) have varied clinical outcomes, and advances in molecular analysis in recent years have highlighted genetic diversity among these patients. Treatment strategies for CN-AML continue to be debated, particularly the suitability of hematopoietic stem cell transplantation (HSCT), and a better understanding of clinical outcomes according to mutational status may help guide treatment decisions.
In a study published in the Journal of Cancer Research and Clinical Oncology, Hong Wang and colleagues evaluated the prognostic impact of AML-related gene mutations in patients with CN-AML and the effect of these molecular markers and MRD status on outcomes after HSCT.1 Here, we are pleased to provide a summary of their results.
Included in the retrospective analysis were 428 patients with CN-AML who achieved complete remission after induction therapy and had complete cytogenetic and molecular data.
The prognostic value of six AML-related gene mutations were evaluated: NPM1, CEBPA, FLT3-ITD, FLT3-TKD, DNMT3A, and C-KIT. Measurable residual disease (MRD) was assessed by multiparameter flow cytometry and/or PCR (polymerase chain reaction). Study endpoints were overall survival (OS) and disease-free survival (DFS).
Study patients had a median age of 43 years (range, 16–73) and most (72.9%) received an induction regimen comprising either idarubicin (8–12 mg/m2) or daunorubicin (60–90 mg/m2) on Days 1–3 and cytarabine (100 mg/m2) on Days 1–7. Consolidation therapy was intermediate/high-dose cytarabine-based chemotherapy (50.5%) or HSCT (49.5%).
Overall, 65.9% of patients had ≥1 gene mutation, 40.2% of whom had a mutation in a single gene, 18.2% had mutations in two genes, and 7.5% had mutations in ≥3 genes. The frequency of each gene mutation is shown in Figure 1.
Figure 1. Frequency of gene mutations in patients with CN-AML*
*Data from Wang et al.1
The risk factors significantly associated with DFS and/or OS in univariate and multivariate analyses are shown in Table 1.
Table 1. Risk factors affecting DFS and OS*
Variable |
DFS |
OS |
||||
---|---|---|---|---|---|---|
3-year DFS, % |
Uni-variate |
Multi-variate HR, |
Median OS, months |
Uni-variate p value |
Multi-variate HR, |
|
Age |
39 vs 72 |
0.013 |
1.87 |
41.3 vs 79.2 |
0.029 |
1.43 |
HB |
68 vs 70 |
0.526 |
— |
60.7 vs 101.4 |
0.039 |
1.50 |
CEBPA |
81 vs 65 |
0.013 |
0.55 |
— vs 60.7 |
< 0.001 |
0.32 |
FLT3-ITD |
59 vs 71 |
0.001 |
2.07 |
36.9 vs 79.2 |
0.001 |
1.70 |
DNMT3A |
55 vs 71 |
0.023 |
1.49 |
44.3 vs 79.2 |
0.242 |
— |
Consolidation therapy |
75 vs 63 |
0.042 |
0.71 |
79.2 vs 39.0 |
< 0.001 |
0.40 |
chemo., chemotherapy; DFS, disease-free survival; HB, hemoglobin; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; mut, mutant; OS, overall survival; wt, wild type; y, years. |
In the multivariate analysis:
In a sub-analysis of patients receiving HSCT consolidation therapy (n = 212), FLT3-ITDmut and MRD before transplantation were each associated with worse 3-year DFS (p = 0.021 and p < 0.001, respectively) and median OS (p = 0.023 and p < 0.001, respectively); however, MRD before transplantation was the only risk factor to be independently associated with poor DFS (p < 0.001) and OS (p < 0.001) after multivariate analysis.
Patients with CEBPAmut/FLT3-ITDwt had a favorable prognosis, with 3-year DFS and OS rates of 84% and 90%, respectively. In contrast, patients with CEBPAwt/FLT3-ITDmut had a poor prognosis, with a 3‑year OS rate of just 44%. Patients with CEBPAwt/FLT3-ITDwt and patients with CEBPAmut/FLT3-ITDmut had intermediate prognoses that were comparable between the two groups.
Similarly, patients with NPM1wt/FLT3-ITDmut had a poor prognosis, with a median OS of just 32.5 months.
Although HSCT consolidation therapy did not improve outcomes for patients with favorable genetics (low risk), it significantly improved outcomes for patients with intermediate or adverse genetics (standard/high risk), with superior median OS (p < 0.001) and DFS (p = 0.044) for standard/high risk transplant recipients compared with those who had not received a transplant.
Molecular analysis revealed an association between FLT3-ITD and CEBPA mutations and either poor or favorable prognoses, respectively, for patients with CN-AML. Combined CEBPAwt/FLT3-ITDmut status confers particularly poor OS. Consolidation with HSCT significantly improves the prognosis of patients with intermediate/adverse genetics, and MRD before transplantation is an independent predictor of outcome for HSCT recipients.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox